Marzan,
Are you certain that Keytruda doesn't make DCVax-L work better. Isn't that being tried at UCLA.
Dr. Liau had a presentation where she clearly indicated that DCVax-L was part of the solution, but others were required to supplement it. It is still my belief that as additional solid cancers are treated with DCVax-L it will be shown that patients living longer actually increase the sales, rather than decreasing them, of BP products found to effectively supplement it.
It doesn't matter if we consider DCVax-L as a supplement to existing therapies, or if we consider those therapeutics as a supplement to DCVax-L, either way people living longer will continue to use these therapeutics until such time as they are deemed to be cancer free.
Gary
Market Data 
Markets 
AI
